Skip to main content

Branded

  • FDA approves Gilead’s hepatitis B treatment Vemlidy

    SILVER SPRINGS, Md. — The Food and Drug Administration has approved Vemlidy (tenofovir alafenamide, TAF, 25 mg), a new once-daily treatment for hepatitis B infection with compensated liver disease from Gilead Sciences. Vemlidy comes with a boxed warning about the risk of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. 
     

  • HDA releases 2 pilot studies in advance of Drug Supply Chain Security Act implementation

    ARLINGTON, Va. — The Healthcare Distribution Alliance  on Thursday presented two viable scenarios out of its Pilot Study for Saleable Returns, a study designed to help pharmaceutical manufacturers and distributors comply with requirements set forth by the Drug Supply Chain Security Act.

  • Allergan launches Taytulla softgel contraceptive

    DUBLIN — Allergan on Thursday announced the launch of its Taytulla norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1mg/20mcg), the first softgel capsule oral contraceptive. 
     

  • Rx-360 launches redesigned website

    WASHINGTON — International pharmaceutical supply chain consortium Rx-360 on Thursday announced the launch of a new website at its annual Rx-360 Conference in Gaylord National Harbor in Maryland. The consortium said the redesign is part of its digital evolution to showcase its industry expertise and support its overall growth. 
     

  • Report: Trump victory could boost pharmaceutical stocks

  • Novartis' Heart Partner app integrated into Walgreens Balance Rewards

    DEERFIELD, Ill. - Walgreens on Monday announced the integration of Novartis' Heart Partner app to its Balance Rewards for Health Choices API.

    "For [heart failure] patients it is sometimes difficult to keep up with a healthier lifestyle and managing their treatment," Walgreens developer evangelist Drew Schweinfurth posted in a blog. "The newly developed Heart Partner app helps coordinate care in a simple and easy way.  The app allows for tracking daily activity and vitals such as blood pressure or weight [and] medication compliance."

  • FDA approves Propeller platform for use with GSK’s Ellipta

     MADISON, Wis. — The Food and Drug Administration has cleared Propeller Health’s Propeller platform — a leading digital solution for respiratory medicine — to be used with GSK’s Ellipta, its dry powder inhaler. 
     

  • Jean Coutu Group continues flu awareness campaign

X
This ad will auto-close in 10 seconds